Precision Oncology: 2022 in Review.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
02 12 2022
Historique:
entrez: 2 12 2022
pubmed: 3 12 2022
medline: 6 12 2022
Statut: ppublish

Résumé

This article presents a review of the major advances and future implications in precision oncology accomplished in 2022 and centers on three primary pillars: advances in (i) rational drug design, (ii) study design, and (iii) novel biomarkers.

Identifiants

pubmed: 36458431
pii: 711165
doi: 10.1158/2159-8290.CD-22-1154
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2747-2753

Informations de copyright

©2022 American Association for Cancer Research.

Auteurs

Ezra Rosen (E)

Memorial Sloan Kettering Cancer Center, New York, New York.

Alexander Drilon (A)

Memorial Sloan Kettering Cancer Center, New York, New York.

Debyani Chakravarty (D)

Memorial Sloan Kettering Cancer Center, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH